Does the Insurance Model of the Future Exclude A Traditional Health Insurance Carrier

 

U.S. insurance is privatized, which presents a host of challenges. Michelle Zettergren, Chief Sales and Marketing Officer of Brighton Health Plan Solutions and Nick Stefanizzi, CEO of Northwell Direct, spoke with Host Kevin Stevenson about opportunities to eliminate the standard middleman of health insurance.

Direct contracting is when employers partner with organizations that provide care for employees without an intermediary between the two. This saves money and ensures access to quality, tailored programs for a better workforce experience. “Judgements are made based on what the clinical needs of that patient are, what’s going to get them the best outcome, and not around how are we going to get the highest return on dollar to our shareholders,” Stefanizzi explained.

With direct contracting, businesses meet employers at a place consistent with the culture. This may involve providing onsite services such as flu shot or telemedicine campaigns. “The employers that are going to win the war for talent are those being seen as making investments in the health, safety, and resiliency of their workforce,” said Stefanizzi.

Brighton supports direct contracting by connecting with employers partnering with integrated delivery systems. They provide claim processing, benefit grids, and customer service to create transparency for the employer and members, which removes the health insurance middleman that often causes fragmented care.

Direct contracting programs are successful because they support and improve the patient-provider relationship, whereas in traditional settings, carriers don’t make data available to allow programs to be successful. Northwell has access to this data and makes it actionable. “The patient is hearing directly from their provider, and the level of adherence is going to be so much higher, the satisfaction so much higher, and it improves the outcome overall,” Zettergren stated.

More Like This Story:

The Rising Tide of Food Allergens

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More